Skip to main content
OpenTrials
Completed

NCT Number: NCT02003898

Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data

The purpose of this study is to evaluate the Threshold Suspend (TS) feature of the Medtronic MiniMed® 530G insulin pump in patients 16 and older with insulin requiring diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medical Investigations, Inc., Little Rock, Arkansas, United States

Loading trial locations.

About this study

Multi-center trial is initiated to observe the Threshold Suspend (TS) feature with a sensor-augmented insulin pump (Medtronic MiniMed® 530G insulin pump) in patients 16 and older with insulin requiring diabetes over a period of one year.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is age 16 or older at time of screening
  • Subject has been diagnosed with diabetes mellitus for at least one year prior to screening.
  • Subject is currently on pump therapy.
  • Subject is transitioning to the 530G insulin pump system with the TS feature turned ON.
  • Subject is willing to complete all study related activities
  • Subject is willing to upload data every 21 days from the study pump
  • Subject must have Internet access and access to a computer system that meets the requirements for uploading the pumps. This may include use of family or friend's computer system with Internet access.
  • Subject is able (by insurance or financial means) to cover the initial investment and ongoing cost of the 530G insulin pump and consumables, CGM, Bayer CONTOUR Next Link RF enabled meter and supplies for the length of the study- 1 year.

Exclusion criteria

  • Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study devices in the last 2 weeks.
  • Subject is a woman of child-bearing potential who has a positive pregnancy test at screening or plans to become pregnant during the course of the study
  • Subject is being treated for hyperthyroidism at time of screening
  • Subject has an abnormality (>1.8mg/dL) in creatinine at time of screening visit
  • Subject has an abnormality (out of reference range) in thyroid-stimulating hormone (TSH) at time of screening visit. If TSH is out of range, Free T3 and Free T4 will be tested. Subject may be included with TSH out of range as long as Free T3 and Free T4 are in normal reference range.
  • Subject has taken any oral, injectable, or IV steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the course of the study
  • Subject is currently abusing illicit drugs
  • Subject is currently abusing prescription drugs
  • Subject is currently abusing alcohol
  • Subject has sickle cell disease or hemoglobinopathy
  • Subject has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening or plans to receive red blood cell transfusion or erythropoietin over the course of study participation
  • Subject diagnosed with current eating disorder such as anorexia or bulimia
  • Subject has been diagnosed with chronic kidney disease that results in chronic anemia
  • Subject is on dialysis

Treatment and study plan

Medtronic MiniMed 530G Insulin Pump

Device

Primary outcomes

  1. Mean Change in A1C From Baseline to 1 Year

    Time frame: 1 year

    Comparison of A1C measurement from baseline to end of study in the CEP266 study population.

    The overall mean change in A1C from baseline will be estimated and compared by a non-inferiority test with an A1C margin of 0.4% and a significance level of 0.025 (one-sided) with the CEP 266 study population.

Secondary outcomes

  1. Mean Change in A1C From Baseline to 1 Year, Baseline A1c Below 7%

    Time frame: 1 year

    Mean Change in A1C From Baseline to 1 Year, for subjects with baseline A1c below 7%.

  2. Mean Change in A1C From Baseline to 1 Year, Baseline A1c of 7% to 9%

    Time frame: 1 year

    Mean Change in A1C From Baseline to 1 Year, for subjects with Baseline A1c of 7% to 9%

  3. Mean Change in A1C From Baseline to 1 Year, Baseline A1c > 9%

    Time frame: 1 year

    Mean Change in A1C From Baseline to 1 year, for subjects with Baseline A1c > 9%

Sponsors and collaborators

Lead sponsor

Medtronic MiniMed, Inc.

Industry

Registry information

Official study title

Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data

Important dates

Study start
2013
Primary completion
2018
Study completion
2018
First posted
Dec 6, 2013
Registry last updated
Mar 5, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.